Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia. The primary objective of this analysis was to characterize the population pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P., Doshi, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953983/
https://www.ncbi.nlm.nih.gov/pubmed/29736889
http://dx.doi.org/10.1007/s10928-018-9592-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953983/
https://www.ncbi.nlm.nih.gov/pubmed/29736889
http://dx.doi.org/10.1007/s10928-018-9592-y

Ejemplares similares